{"title":"默克公司扩大肿瘤产品组合","authors":"None Laura Howes","doi":"10.1021/cen-10137-buscon16","DOIUrl":null,"url":null,"abstract":"Merck KGaA has signed a deal with the Chinese firm Jiangsu Hengrui Pharmaceuticals to bring to market two of Hengrui’s oncology drugs: HRS-1167, a PARP1 inhibitor, and SHR-A1904, an antibody-drug conjugate. For $169 million up front, Merck gets the rights to both drugs outside China. Merck says that the acquisition of HRS-1167 aligns with its in-house expertise in DNA damage response. The firm is exploring whether the inhibitor could be combined with other drugs for maximum effect.","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"29 8","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Merck KGaA expands oncology portfolio\",\"authors\":\"None Laura Howes\",\"doi\":\"10.1021/cen-10137-buscon16\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Merck KGaA has signed a deal with the Chinese firm Jiangsu Hengrui Pharmaceuticals to bring to market two of Hengrui’s oncology drugs: HRS-1167, a PARP1 inhibitor, and SHR-A1904, an antibody-drug conjugate. For $169 million up front, Merck gets the rights to both drugs outside China. Merck says that the acquisition of HRS-1167 aligns with its in-house expertise in DNA damage response. The firm is exploring whether the inhibitor could be combined with other drugs for maximum effect.\",\"PeriodicalId\":9517,\"journal\":{\"name\":\"C&EN Global Enterprise\",\"volume\":\"29 8\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"C&EN Global Enterprise\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1021/cen-10137-buscon16\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"C&EN Global Enterprise","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/cen-10137-buscon16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Merck KGaA has signed a deal with the Chinese firm Jiangsu Hengrui Pharmaceuticals to bring to market two of Hengrui’s oncology drugs: HRS-1167, a PARP1 inhibitor, and SHR-A1904, an antibody-drug conjugate. For $169 million up front, Merck gets the rights to both drugs outside China. Merck says that the acquisition of HRS-1167 aligns with its in-house expertise in DNA damage response. The firm is exploring whether the inhibitor could be combined with other drugs for maximum effect.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
